➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Mallinckrodt
Express Scripts
Baxter
AstraZeneca

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,927,044

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,927,044
Title: IL-1 receptor based cytokine traps
Abstract:Fusion polypeptides capable of binding interleukin-1 (IL-1) to form a nonfunctional complex are provided and nucleic acid molecules encoding the fusion polypeptides. The fusion ploypeptides form dimers to function as IL-1 antagonists.
Inventor(s): Stahl; Neil (Carmel, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:10/282,162
Patent Claims:1. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:33.

2. A fusion polypeptide encoded by the nucleic acid molecule of claim 1.

3. The nucleic acid molecule of claim 1, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:34.

4. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:35.

5. A fusion polypeptide encoded by the nucleic acid molecule of claim 4.

6. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:36.

7. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:37.

8. A fusion polypeptide encoded by the nucleic acid molecule of claim 7.

9. The A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:38.

10. The nucleic acid of claim 1, 4, or 7, wherein nucleotide 1979 is changed from A to C.

11. A fusion polypeptide encoded by the nucleic acid molecule of claim 10.

12. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:39.

13. A fusion polypeptide encoded by the nucleic acid molecule of claim 12.

14. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:40.

15. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:41.

16. A fusion polypeptide encoded by the nucleic acid molecule of claim 15.

17. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:42.

18. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:43.

19. A fusion polypeptide encoded by the nucleic acid molecule of claim 18.

20. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:44.

21. The nucleic acid of claim 12, 15, or 18, wherein nucleotide 1043 is changed from A to C.

22. A fusion polypeptide encoded by the nucleic acid molecule of claim 21.

23. A composition capable of binding IL-1 to form a non-functional complex comprising a multimer of the fusion polypeptide of any of claims 2, 5, 8, 11, 13, 16, 19, or 22.

24. The composition of claim 23, wherein the multimer is a dimer.

25. A vector comprising the nucleic acid molecule of any of claims 1, 4, 7, 10, 12, 15, 18, and 21.

26. An expression vector comprising the nucleic acid molecule of any of claims 1, 4, 7, 10, 12, 15, 18, and 21 operatively linked to an expression control sequence.

27. A host-vector system for the production of a fusion polypeptide, comprising the expression vector of claim 26 in a suitable host cell.

28. The host-vector system of claim 27, wherein the suitable host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell.

29. A method of producing a fusion polypeptide that comprises growing cells of the host-vector system of claim 27, under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.

30. The host-vector system of claim 28, wherein the suitable host cell is a CHO cell.

Details for Patent 6,927,044

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2018-09-25 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Johnson and Johnson
Colorcon
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.